# Liver disease, fibrosis and noninvasive assessment

[Home](../README.md) · [Metabolic health and longevity](../WATCHLIST.md#metabolic-health) · [Calendar](../MILESTONES.md)

Tags: [Screening and earlier detection](../BROWSE.md#screening) · [Drugs and biologics](../BROWSE.md#drugs)

## Current state

A new placebo-controlled Kylo-0603 trial will measure MRI liver-fat reduction. Earlier senolytic biopsy signals and larger FGF21/THRβ programs remain distinct from proven reductions in liver complications; complete patient results and harms remain pending.

Status: active. Initial baseline completed September 12, 2026. Topic ID: `liver`.

## Questions to follow

- Follow human therapies for metabolic dysfunction-associated steatotic liver disease (MASLD), steatohepatitis (MASH), fibrosis and cirrhosis, including new combinations and indications.
- Track noninvasive diagnosis, fibrosis staging and response assessment using blood markers, elastography and imaging. Separate liver fat, inflammation, fibrosis, portal hypertension and clinical complications.
- Cross-link [GLP-1](03_glp1.md) and [visceral/liver-fat research](06_localized_fat.md). Relevant informal claims remain eligible under the [rumor policy](../README.md#rumors-and-informal-signals).

## Programs and next milestones

### Focused update — 2026-10-16

<span class="note-anchor" id="note-2026-10-16-kylo0603-phase2-registration"></span>

#### Kylo-0603 registers a placebo-controlled liver-fat trial

**NCT07878091 / Kylo-0603-IIa-01, first posted October 16.** Shanghai Chia Tai Tianqing sponsors a masked randomized Phase 2a trial in **120 adults with MASLD and overweight/obesity in China**, comparing daily oral **Kylo-0603 8, 12 or 16 mg** with placebo for **12 weeks**.

Kylo-0603 is described as a liver-targeted **GalNAc-conjugated thyroid-hormone receptor β agonist**. Primary is percentage change in **MRI-PDFF liver-fat content at week 12**. Secondary measures include liver stiffness, LDL cholesterol, liver enzymes and other biomarkers. Neither liver-fat reduction nor a stiffness/LDL change alone establishes fibrosis reversal, fewer liver complications or cardiovascular benefit.

The record is **not yet recruiting**. Start **November 15, 2026** and primary/final completion **August 15, 2027** are estimates; no results or participant adverse-event rates are posted. Earlier healthy-volunteer work is historical context, not a new October efficacy result. No U.S. approval or availability is established.

**Sources:** [Source 1](https://clinicaltrials.gov/study/NCT07878091); [Source 2](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0527/2026052700522.pdf).

**Remaining gaps:** Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered September 5–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 144 records across 2 pages of the bounded ClinicalTrials.gov query, plus 13 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; The new Kylo-0603 patient trial is the selected formal entrant. Prior TRUTH, ARO-INHBE, ALN-CIDEB and efimosfermin findings were deduplicated. Current EMA Wegovy overview still does not resolve the saved September MASH variation; no approval/rejection inferred from omission. Full papers/supplements, clinical-outcomes and noninvasive-test utility census remain gaps.

**Informal-source coverage:** Saved Wegovy CHMP omission inference revisited against EMA current page; outcome remains unconfirmed and no repeat alert. Targeted informal searches supplied no separate new original claim selected. Complete conference/investor audio and informal source census remain incomplete.

[Full coverage record](../updates/2026-10-16_scheduled_research_update.md).


### Focused update — 2026-10-13

<span class="note-anchor" id="note-2026-07-14-nebula1-efimosfermin-baseline"></span>

#### NEBULA-1 tests clinical liver outcomes in compensated MASH cirrhosis

**Baseline recovery, checked October 13 — NEBULA-1, NCT07701993 / GSK 306300.** GSK's randomized masked placebo-controlled Phase 3 trial plans **1,740 adults aged 18–75 with compensated MASH cirrhosis**. Efimosfermin alfa is an investigational FGF21 analogue given subcutaneously.

Primary is time to an adjudicated composite of **all-cause mortality, liver transplantation and significant hepatic decompensation**, over up to **356 weeks**. Liver stiffness, ELF, metabolic measures, quality of life and harms are secondary; biomarker improvement alone will not prove this primary benefit.

The September 30 registry and original GSK protocol say **recruiting**, with actual start **July 22, 2026**. Estimated primary completion is **June 23, 2033**, final **August 24, 2033**. No results; U.S. treatment remains investigational. This earlier program fills a saved coverage gap rather than a new October launch.

A secondary CTIS mirror displays an October 12 EU authorization date and a different 1,468 planned total; the primary EMA linked search did not expose the decision details. That regional claim/count is **not promoted as verified** or substituted for the source-backed 1,740 protocol count.

**Sources:** [Source 1](https://clinicaltrials.gov/study/NCT07701993); [Source 2](https://www.gsk-studyregister.com/trials/306300); [Source 3](https://euclinicaltrials.eu/search-for-clinical-trials/?EUCT=2026-525755-82&lang=en); [Source 4](https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf).

**Remaining gaps:** Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 138 records across 2 pages; incidental studies excluded. Named topic records refreshed: 12. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; EMA current Wegovy overview and available minutes still do not resolve the September MASH variation. September minutes expected after the October CHMP; no rejection/delay inferred from omission. Secondary CTIS mirror NEBULA authorization not independently established from primary EMA; record discrepancy retained. Worldwide fibrosis/noninvasive utility and complete FGF21 harms corpus remain incomplete.

**Informal-source coverage:** Revisited saved September 18 Reddit inference about Wegovy CHMP omission against current EMA page and available agendas/minutes. Outcome remains unconfirmed; no repeat alert. Searched MASH informal development claims without selecting a new attributable original signal; full audio remains incomplete.

[Full coverage record](../updates/2026-10-13_scheduled_research_update.md).


### Focused update — 2026-10-09

<span class="note-anchor" id="note-2026-10-01-truth-senolytics"></span>

#### Small randomized senolytic MASH trial reports a biopsy signal and more adverse events

**TRUTH / NCT05506488, published October 1; recovered in this October 9 overlap review.** Amsterdam investigators randomized **31 people with fibrotic MASH (F2–F3)** to intermittent dasatinib plus quercetin or placebo for **21 weeks**.

Fibrosis improvement without MASH worsening occurred in **8/17 (47%) versus 1/14 (7%)**: risk difference **40 percentage points (95% CI 8.2–64.5)**, reported p=0.021. The reported risk ratio was **6.59 (95% CI 0.93–46.53)**; preserve this wide interval despite the different p-value method. MASH resolution was **9/17 (53%) versus 1/14 (7%)**, risk difference **46 points (95% CI 13.6–69.3)**.

Adverse events occurred in **82% versus 43%**; one active participant stopped because of GI symptoms/fatigue. One serious event, planned knee surgery, was considered unrelated; severe dysphagia was attributed to previously undisclosed malignancy and that participant withdrew. Diabetes prevalence was imbalanced (**76.5% versus 35.7%**). Small size, short follow-up and biopsy surrogates limit inference: this does not establish fewer liver complications, a durable cure or lifespan extension. The combination has no U.S. MASH/longevity approval. Larger replication timing is undated.

**Additional limitations:** Four participants lacked follow-up biopsy and were counted as nonresponders in the primary analysis. A worst-case missing-data sensitivity gave RR 3.29 (95% CI 0.83–13.08), p=0.068. Noninvasive FIB-4, ELF and liver-stiffness comparisons were not significant. Histologic response is hypothesis-generating pending larger replication.

**Sources:** [Primary source 1](https://www.nature.com/articles/s42255-026-01643-4); [Primary source 2](https://clinicaltrials.gov/study/NCT05506488).

**Remaining gaps:** Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Liver discovery returned 171 records; first 100 downloaded; selected relevant records screened, remaining page not reviewed. Updated saved RNA-interference protocols rechecked. September 29 TRIUMPH-1 full methods/CI access gap and worldwide noninvasive-screening/approval coverage remain.

**Informal-source coverage:** October 9 original r/Futurology post located: https://www.reddit.com/r/Futurology/comments/1x1lwvz/in_a_world_first_in_a_phase_2_trial_with_31/ . It frames histologic MASH resolution as a 50+% cure rate; original trial supports a short-term biopsy outcome, not proven durable cure. This is interpretation of a published paper, not a new clinical leak. Wider podcast audio and existing European Wegovy-MASH rumor not comprehensively refreshed.

[Full coverage record](../updates/2026-10-09_scheduled_research_update.md).


### Focused update — 2026-10-06

<span class="note-anchor" id="note-2026-10-06-aroinhbe"></span>

#### ARO-INHBE adds a randomized MASH phase 2 plan

**Source/event date: October 6, 2026. Evidence: new phase 2 registration.** AROINHBE-2001 plans 252 adults with suspected MASH, BMI 30–50, with or without diabetes and with stable background GLP-1/GIP therapy allowed. Randomized double-masked ARO-INHBE dose/schedule groups are compared with matched placebo. The primary endpoint is MRI-PDFF liver-fat change at week 48; histologic MASH resolution and fibrosis improvement are secondary. NOT_YET_RECRUITING; September 2026 start is still estimated and elapsed. Primary/final completion is estimated October 2029. No human results or safety estimates are posted. Registration establishes a liver development plan, not proven fibrosis benefit, fewer complications or U.S. approval.

[Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07859813) · [Source 2](https://clinicaltrials.gov/study/NCT07859813)

<span class="note-anchor" id="note-2026-10-02-alncideb"></span>

#### ALN-CIDEB registers a large MASLD study with primary safety endpoints

**Source/event date: October 2, 2026. Evidence: new phase 3 registration.** Regeneron’s ALN-CIDEB-MASLD-2604 plans 1,500 adults with MASLD and FibroScan liver stiffness 6–20 kPa. The randomized quadruple-masked study compares two ALN-CIDEB dose levels with placebo. Registered primary endpoints are incidence and severity of treatment-emergent adverse events through week 64; week-52 FibroScan fat/stiffness and liver enzymes are secondary. NOT_YET_RECRUITING, with November 6, 2026 estimated start and March 3, 2029 completion.

This registration does not show new human efficacy, clinical-event prevention, marketing approval or first dosing. MASLD inclusion by noninvasive stiffness is distinct from a biopsy-confirmed F2–F3 MASH pivotal population. The large phase designation does not convert biomarkers into clinical benefit; no results are posted.

[Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07854782) · [Source 2](https://clinicaltrials.gov/study/NCT07854782)

**Coverage:** 2026-10-06: MASH trial October2026 lanifibranor efruxifermin pegozafermin; 2026-10-06: ClinicalTrials.gov September5–October6 interventional MASH/NASH first50; 2026-10-06: Wegovy MASH SeptemberCHMP EMA outcome; EPAR current SmPC; 2026-10-06: Reddit OctoberMASH and saved September18 CHMP original

**Remaining gaps:** September5–October6 overlap; first50 recent MASH/NASH registry records and direct new ALNCIDEB/AROINHBE protocols read. Efruxifermin/pegozafermin/survodutide ongoing records are not new results. Full cirrhosis/noninvasive test census remains incomplete.; Wegovy EPAR and September21 product information checked: no steatohepatitis indication located. This does not determine the September CHMP variation outcome or infer rejection. NATiV3 Q4 topline remains forecast, no result verified.

**Informal-source coverage:** Original September18 u/kiyomoris CHMP-omission inference revisited; current SmPC does not resolve the actual procedure disposition. No approval/rejection inferred. Original full EASL podcasts/talk audio not appraised.

[Full coverage record](../updates/2026-10-06_scheduled_research_update.md).


### Focused update — 2026-10-02

#### New joint MASH guidance addresses resmetirom and semaglutide selection

**Source/event date:** 2026-09-28. **Evidence:** Professional-society clinical guidance; not a new trial.

The September 28 EASL–EASD–EASO guidance addresses selection, initiation, monitoring and stopping of resmetirom and weekly semaglutide 2.4 mg as MASH-targeted treatments. It recommends individualizing choice by metabolic disease, body composition, other conditions and preferences; the strength of the recommendation should not be mistaken for high-certainty comparative evidence. This is an interpretation of existing evidence, not a new randomized head-to-head trial or proof of reduced liver-related deaths. Existing U.S. indications remain separate from European review and access. The guidance does not resolve the previously tracked September CHMP outcome. Further clinical-outcome follow-up remains necessary.

**Next milestone:** NATiV3 Q4 2026 sponsor forecast; ESSENCE clinical-event follow-up remains ongoing.

[Source 1](https://www.journal-of-hepatology.eu/article/S0168-8278%2826%2902877-1/fulltext).

**Related findings:**

- [DR10624 adds a triglyceride trial in diabetic kidney disease](07_cardiovascular.md#dr10624-adds-a-triglyceride-trial-in-diabetic-kidney-disease).

**Coverage:** MASH September30 October 2026 new trials and EASL EASD EASO guidance; EMA Wegovy September2026 CHMP MASH outcome; EASL Talk Liver to Me September30 resmetirom semaglutide.

**Remaining gaps:** EU September Wegovy MASH procedure outcome still not verified; an agenda or guidance publication does not establish approval. Broader fibrosis, cirrhosis and noninvasive-test registry census incomplete. Guidance full recommendation tables not systematically appraised.

**Informal-source coverage:** EASL September30 podcast page verified: Debbie Shawcross with Andreea Ciudin, Amalia Gastaldelli and Frank Tacke. Show notes discuss guidance; full audio not reviewed and no new rumor inferred. Existing CHMP-omission Reddit inference remains unconfirmed.

**Next update:** NATiV3 Q4 2026 sponsor forecast; ESSENCE clinical-outcome follow-up ongoing. September CHMP outcome remains unverified.

[Full coverage record](../updates/2026-10-02_scheduled_research_update.md).

### Focused update — 2026-09-29

#### Singapore adds a Wegovy indication for noncirrhotic MASH

**Source date:** 2026-09-23. **Event date:** exact date not disclosed. **Date basis:** Announcement date; exact HSA action date not independently verified. **Evidence:** Sponsor announcement of regulatory approval.

Novo announced HSA approval of weekly injectable semaglutide 2.4 mg for adults with noncirrhotic MASH and F2–F3 fibrosis, with diet and activity. The decision draws on the existing ESSENCE week-72 biopsy evidence, not a newly completed outcomes trial.

**Limitations:** Not an indication for cirrhosis; geographic approval does not imply local stock or reimbursement. Liver-fat or biopsy improvement is separate from preventing decompensation, transplant or death. HSA decision letter was not independently retrieved.

**Safety:** No new safety analysis; known gastrointestinal tolerability and indication-specific prescribing information remain relevant.

**U.S. status:** Existing U.S. MASH approval is separate and unchanged.

**Next milestone:** ESSENCE part 2 continues to 240 weeks for liver-related clinical events; this release does not give a new readout date.

[Novo Singapore approval announcement](https://www.prnewswire.com/apac/news-releases/novo-receives-singapore-approval-for-wegovy-as-first-treatment-for-mash-with-liver-fibrosis-302886853.html).

**Coverage:** Singapore regulatory announcement, CHMP agenda follow-up, NATiV3/MASH discovery and September announcements.

**Remaining gaps:** Independent HSA letter and CHMP September MASH outcome not recovered. Global fibrosis and noninvasive-test review incomplete. AASLD page showed conflicting 2025/2026 dates and was not treated as new study evidence.

**Informal-source coverage:** CHMP Reddit inference remains unresolved; old lanifibranor investor timing/odds discussion not independent evidence. https://www.reddit.com/r/biotech_stocks/comments/1uz61q4/inventiva_pharma_update/ . Original conference/podcast recordings not reviewed.

**Next update:** NATiV3 Q4 2026 sponsor forecast; ESSENCE clinical-outcome follow-up ongoing.

[Full coverage record](../updates/2026-09-29_scheduled_research_update.md).

### Focused update — 2026-09-27

No additional finding was verified in the reviewed sources. Coverage remains partial; this is not a full-topic “no news” conclusion.

**Coverage:** MASH/liver human-trial discovery and saved Wegovy CHMP ambiguity follow-up; EMA current EPAR searched, Novo CMD/TGM/NATiV3 repeats deduplicated.

**Remaining gaps:** Wegovy September CHMP outcome still unverified: current overview contains no MASH entry; absence is not a rejection. Full minutes/updated assessment not recovered. Pegozafermin, efimosfermin and noninvasive testing/clinical-outcome census incomplete.

**Informal-source coverage:** Revisited September18 original Reddit CHMP omission claim; September23 post claims Singapore MASH approval but regulator corroboration not retrieved, so retained as discovery gap rather than approval fact. MASH podcast searches mainly CME, reviews and personal stories; no full audio review. Original: https://www.reddit.com/r/NovoNordisk_Stock/comments/1wjxoxg/wegovys_mash_indication_was_for_adoption_at_chmp/ ; https://www.reddit.com/r/NovoNordisk_Stock/comments/1wo0wv6/wegovy_expansion_mash_approval_in_singapore_72_mg/

[Full coverage record](../updates/2026-09-27_scheduled_research_update.md).

### Focused update — 2026-09-22

**Registry clarification:** RESTORE-MASH is [NCT07427680](https://clinicaltrials.gov/study/NCT07427680), a randomized, double-masked phase 1/2 study with 99 planned participants. The May 19 record lists recruiting, actual start March 3, 2026, estimated primary completion March 2028 and final completion June 2028; no results. This closes the identifier gap for the already recorded TGM-312 program.

#### New liver-development plans target MASH and alcohol-related disease

**Source date:** 2026-09-21. **Event date:** 2026-09-21. **Evidence:** Sponsor development forecast.

Novo plans a Phase 3 MASH program for UBT251 and a dedicated efruxifermin alcohol-related liver disease trial during 2027. The CMD presentation places UBT251 in F2–F3 disease and efruxifermin in advanced fibrosis/compensated cirrhosis. Existing SYNCHRONY OUTCOME results are forecast around 2030.

**Limitations:** Plans do not establish initiation or clinical benefit in the new indications. Historical efruxifermin biopsy data displayed in the presentation are not new September results.

**Safety:** No new safety dataset for the planned programs.

**U.S. status:** No U.S. approval established for UBT251 or efruxifermin.

**Next milestone:** UBT251 Phase 3 MASH and efruxifermin ALD study initiation: 2027 sponsor forecasts; specific dates and identifiers pending.

[Novo Cardiovascular and liver CMD, slides 10, 18–19](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/capital-markets-day/2026/CVD-liver-presentation.pdf).

**Coverage:** Novo September 21 MASH/ALD plans, EMA September meeting, efruxifermin registry timing, TGM-312 registry-identifier recovery and ATHENA status gap.

**Remaining gaps:** Wegovy September EU procedure outcome not explained in retrieved CHMP highlights; no approval/rejection inferred. ATHENA discontinuation lead not resolved by current primary record, which still predates alleged news. SYNCHRONY RW completion windows elapsed without posted result; no assumed readout. Noninvasive liver-test outcome/comparative census incomplete; no full CMD audio review.

**Informal-source coverage:** Read September 18 original Reddit post noticing Wegovy's absence from meeting highlights; verified agenda/absence and retained outcome uncertainty. New CMD liver plans are sourced to official slides, not Reddit interpretation.

[Full coverage record](../updates/2026-09-22_scheduled_research_update.md).

**Next update:** UBT251 MASH phase 3 and efruxifermin alcohol-related liver study starts are forecast for **2027**; NATiV3 topline remains **Q4 2026**. TGM-312 registry primary completion is estimated **March 2028**.

### Focused update — 2026-09-18

#### RNAi liver program advances into MASH patient cohorts

**Source date:** 2026-09-03. **Evidence:** Historical evidence recovered.

TGM-312 adds a liver-targeted SLC25A5 RNAi program to the watch. The phase 1/2 RESTORE-MASH study advanced from single-dose cohorts of healthy volunteers to multiple-dose cohorts of patients with MASH after a monitoring review. Four healthy-volunteer cohorts had been dosed; the participant count was not reported.

**Limitations:** No numerical human liver-efficacy findings were provided. Preclinical combination and fibrosis results remain animal evidence. The registry identifier was not verified.

**Safety:** The sponsor reports no serious or severe adverse events in the healthy-volunteer cohorts; this is limited early safety evidence.

**U.S. status:** Investigational.

**Next milestone:** The sponsor forecasts interim results from MASH patient cohorts during 2027.

[Tangram September3 original release](https://www.globenewswire.com/news-release/2026/09/03/3355868/0/en/tangram-therapeutics-announces-progression-to-patient-cohorts-in-phase-1-2-restore-mash-trial-of-tgm-312-and-appointment-of-dr-sonya-montgomery-as-chief-development-officer.html).

**Coverage:** TGM-312 human development; NATiV3 and Paris MASH updates; discovery searches for new liver programs. The Duke resmetirom/HFpEF announcement was dated August 27, not September 16. This is a focused review, not a complete re-review of every program.

**Remaining gaps:** Pegozafermin, efruxifermin, efimosfermin and noninvasive-test publications were not comprehensively refreshed. The EMA draft agenda for September 14–17 includes Wegovy for MASH, but no final CHMP action was verified. The RESTORE-MASH registry identifier was not verified.

**Informal-source coverage:** Liver podcast searches mainly found older CME and forecasts; no original new development claim verified. Not a complete audio/transcript sweep.

[Full coverage record](../updates/2026-09-18_scheduled_research_update.md).

### Focused update — 2026-09-14

**2026-09-02 — Older context added: NATiV3 reaches final patient visit.** Inventiva’s September 2 announcement says the last NATiV3 participant completed the 72-week visit. The main cohort included 1,009 adults with noncirrhotic MASH and F2–F3 fibrosis, plus 410 exploratory participants. **No efficacy or safety results were reported.** Topline is sponsor-targeted for Q4 2026; a possible H1 2027 filing depends on results. [Sponsor announcement](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf). The July 2 [NCT04849728 registry](https://clinicaltrials.gov/study/NCT04849728) retains a September 2027 completion estimate encompassing an additional 48-week extension safety follow-up; this is distinct from the 72-week topline milestone. Its estimated enrollment of 1,000 differs from the later sponsor counts. Neither registry completion nor the final visit guarantees a publication date. Added September 14 as missing earlier context, not same-day news.

**Coverage:** Lanifibranor NATiV3 final patient visit, September 2, added as older missing development context. The registry includes extension safety follow-up beyond the 72-week milestone; Q4 topline remains a forecast. Estimated registry enrollment differs from the later sponsor count. Paris MASH announcements are not pivotal results. No systematic new biomarker-publication review. This was a focused refresh, not a complete re-review of every program.

Checked sources: [Source 1](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf); [Source 2](https://clinicaltrials.gov/study/NCT04849728); [Source 3](https://inventivapharma.com/investors/); [Source 4](https://ir.madrigalpharma.com/news-releases).

**Next expected update:** Combination-study start **Q4 2026**; resmetirom cirrhosis results **2027**; ESSENCE outcomes completion **2029** (sponsor forecasts).

### Initial evidence brief — September 12, 2026

**Current position.** MASH now has approved therapies for selected noncirrhotic patients, while preventing decompensation and treating established cirrhosis remain major trial questions. Histologic improvement is encouraging but differs from fewer transplants, liver cancers or deaths. The diagnostic frontier is whether less invasive tests can reliably identify disease and treatment response, and ultimately help improve outcomes.

### Historical baseline addition — reviewed 2026-10-03

#### Pemvidutide PERFORMA phase 3 enrollment began in August

**Source/event date:** 2026-08-03. **Date basis:** Sponsor enrollment-initiation announcement. **Evidence:** Historical development baseline; not October news or a new efficacy readout.

Altimmune announced that enrollment had begun in PERFORMA, a global randomized, double-blind, placebo-controlled phase 3 trial of pemvidutide in MASH with moderate to advanced fibrosis. The program will assess fibrosis improvement, MASH resolution and clinical outcomes. Its current sponsor pipeline also describes active enrollment. This establishes a later MASH development stage than the older IMPACT phase 2b evidence; the obesity MOMENTUM results remain a separate indication and study.

**Limitations and safety:** Initiation does not establish efficacy, fewer liver complications or long-term safety. Histology and biomarkers remain distinct from clinical outcomes; the announcement is sponsor evidence, with no new outcome effect estimate. Breakthrough Therapy designation is not marketing approval.

**U.S. status:** Investigational; no pemvidutide approval established.

**Next milestone:** PERFORMA 52-week data forecast for **2029** by the sponsor, not a guaranteed publication or approval date.

[Altimmune August 3 primary announcement](https://rss.globenewswire.com/news-release/2026/08/03/3337439/0/en/altimmune-initiates-performa-phase-3-trial-of-pemvidutide-in-patients-with-mash.html); [Current sponsor pipeline](https://altimmune.com/pipeline/).

**Coverage:** Selected development-stage reconciliation for the Medical frontier visualization. Full-topic successful-check timestamps remain unchanged; this is not a comprehensive liver monitoring run.

**Rezdiffra / resmetirom — Madrigal, liver-directed thyroid-hormone-receptor beta agonist.** FDA approved it in March 2024 for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. MAESTRO-NASH, [NCT03900429](https://clinicaltrials.gov/study/NCT03900429), is randomized and placebo-controlled; FDA's pivotal efficacy population contained 888 patients with F2–F3 fibrosis. The month-12 biopsy endpoints assessed MASH resolution without worse fibrosis and fibrosis improvement without worse MASH. Its accelerated approval requires confirmation of clinical benefit. Common adverse effects include gastrointestinal symptoms; liver toxicity, gallbladder-related events and interactions with statins also matter. [FDA evidence and safety](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-rezdiffra), [July 2026 development/approval status](https://ir.madrigalpharma.com/static-files/491a260f-ee81-4b55-9e8f-69f6edf61cd9).

**Resmetirom in compensated cirrhosis — a major outcomes watch.** MAESTRO-NASH-OUTCOMES, [NCT05500222](https://clinicaltrials.gov/study/NCT05500222), completed enrollment in October 2024 with 845 participants. It is a blinded randomized comparison of resmetirom versus placebo, with liver-related clinical events as the primary endpoint. This is distinct from the original noncirrhotic indication. Madrigal's **July 30, 2026 presentation targets results in 2027**. Open-label cirrhosis findings and improvements in risk scores cannot substitute for that randomized result. [Enrollment/design announcement](https://ir.madrigalpharma.com/node/15871/pdf), [current 2027 target, slide 12](https://ir.madrigalpharma.com/static-files/491a260f-ee81-4b55-9e8f-69f6edf61cd9).

**Wegovy / semaglutide — approved liver indication, outcomes still pending.** FDA granted accelerated approval on **August 15, 2025** for noncirrhotic MASH with F2–F3 fibrosis. ESSENCE, **NCT04822181**, provides the Phase 3 evidence: at 72 weeks, MASH resolution without worsening fibrosis occurred in **62.9% versus 34.1%**, and fibrosis improvement without worsening MASH in **37.0% versus 22.5%**. These biopsy outcomes do not yet establish prevention of decompensation. Novo expects the longer outcomes portion to complete in **2029**, a study-completion forecast rather than a publication deadline. Keep liver-specific follow-up here and cross-link obesity news. [FDA approval letter](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s024ltr.pdf), [original ESSENCE paper](https://www.nejm.org/doi/10.1056/NEJMoa2413258), [Q2 2026 timing, slide 42](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q2-2026-Full%20presentation.pdf).

**Efruxifermin / EFX — FGF21 analogue, now within Novo/Akero.** The 181-person, placebo-controlled SYMMETRY Phase 2b trial, **NCT05039450**, studied compensated MASH cirrhosis. It **missed the primary 36-week fibrosis endpoint**. At 96 weeks, the higher-dose arm showed fibrosis improvement without worsening MASH in **29% versus 11%**; that later secondary result is not a successful primary endpoint or proof of fewer clinical complications. Gastrointestinal adverse events were more common. [Full SYMMETRY paper](https://www.nejm.org/doi/10.1056/NEJMoa2502242).

Phase 3 SYNCHRONY includes Histology (**NCT06215716**, F2–F3), Real-World (**NCT06161571**, noninvasively identified disease) and Outcomes (**NCT06528314**, cirrhosis). The current sponsor presentation confirms ongoing trials and exploration of GLP-1 combinations, but only describes readouts over coming years. **No exact next EFX readout date is verified.** It remains investigational in the U.S. [Current development plan, slides 43–44](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q2-2026-Full%20presentation.pdf), [trial-program description](https://akerotx.com/clinical-trials/).

**Other human-stage mechanisms.** Pegozafermin's Phase 3 ENLIGHTEN MASH program is an additional FGF21 watch. Madrigal is also developing combinations: its current pipeline targets a resmetirom/ervogastat interaction study in **Q4 2026**, then Phase 2 in **2027** following regulatory discussions. These are development plans, not combination efficacy or approval. [Pegozafermin pipeline](https://89bio.com/pipeline/), [Madrigal pipeline](https://www.madrigalpharma.com/pipeline/).

**Noninvasive assessment — a separate research question.** In August 2025, FDA accepted a letter of intent to qualify vibration-controlled transient-elastography liver stiffness as a reasonably likely surrogate endpoint in noncirrhotic MASH trials. This is **the first qualification step**, not completed validation or authorization to replace every biopsy. Watch the qualification plan, external validation, changes during treatment and prediction of actual complications. Better test accuracy alone does not demonstrate benefit from screening an unselected population; changes in stiffness also should not automatically be labeled fibrosis reversal. [FDA qualification announcement](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-accepts-proposal-reasonably-likely-surrogate-endpoint-mash-all-cause-mortality-or-liver-related).

### Expected next updates

| Program/question | Timing label and next meaningful event |
| --- | --- |
| Resmetirom/ervogastat | **Sponsor targets:** interaction-study start Q4 2026; Phase 2 start 2027. Pipeline source above. |
| MAESTRO-NASH-OUTCOMES | **Sponsor target: 2027 results.** Event-driven; cirrhosis benefit remains unproven. |
| ESSENCE outcomes | **Sponsor-estimated completion: 2029.** Not a promised release date. |
| EFX, pegozafermin, noninvasive-test qualification | **No firm next date verified** in this check; refresh trial records and sponsor/regulator updates. |

## Rumors and informal signals

### September 29 informal-source check

**Wegovy European MASH review — unconfirmed.** Agenda remains verified, September procedure outcome unresolved. Singapore approval does not resolve the EU procedure.

[Source](https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-14-17-september-2026_en.pdf).

**September 27 status check:** Existing claims remain unconfirmed; no material status change or repeat alert.

- **Wegovy_2026-09-18_CHMP-MASH-outcome-unclear — unconfirmed:** EMA current Wegovy overview does not resolve the September MASH procedure; absence is not evidence of rejection or delay. [EMA current Wegovy EPAR](https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy).

### 2026-09-18 — Speculation/inference

**Speculation/inference.** An anonymous r/NovoNordisk_Stock post observed that Wegovy's MASH variation was on the September CHMP adoption agenda but absent from meeting highlights; the reason and outcome remain unclear.

Original Reddit post dated September 18; no speaker identity or recording timestamp. Agenda placement and omission can be checked; neither establishes approval, rejection, withdrawal or delay. Do not import the post's other brand/geography assertions without separate verification. [Source](https://www.reddit.com/r/NovoNordisk_Stock/comments/1wjxoxg/wegovys_mash_indication_was_for_adoption_at_chmp/).

**Next check:** September CHMP minutes or an updated Wegovy EPAR.

**Status history:** 2026-09-22 — unconfirmed. Stable key: `Wegovy_2026-09-18_CHMP-MASH-outcome-unclear`.

## Dated history

### 2026-10-02 — Scheduled focused review

1 newly recorded findings or milestones; primary evidence, uncertainty and incomplete coverage are detailed above and in the [run record](../updates/2026-10-02_scheduled_research_update.md). Full-topic successful-check dates remain unchanged.

- **2026-09-29:** 1 sourced entries, 0 cross-topic links and 1 informal-source checks. [Coverage and gaps](../updates/2026-09-29_scheduled_research_update.md).

- **2026-09-27:** 0 sourced entries and 0 cross-topic links from a focused scheduled check. [Coverage and remaining gaps](../updates/2026-09-27_scheduled_research_update.md).

- **2026-09-22:** Focused scheduled research retry; 1 sourced entries and 0 cross-topic links. [Coverage and gaps](../updates/2026-09-22_scheduled_research_update.md).

### Dated findings and coverage

- **Checked September 12, 2026:** Selective baseline; sources include FDA decisions, trial publications and current sponsor materials. Registry pages did not consistently render full details, so no unverified registry completion date is used. Pegozafermin and comparative noninvasive-test performance need a deeper follow-up; informal-source coverage was incidental, with no rumor recorded in this baseline.

### 2026-09-14 — Ad-hoc focused review

Lanifibranor NATiV3 final patient visit, September 2, added as older missing development context. Original event dates and sources are recorded above; unchanged historical trial results remain dated. The registry includes extension safety follow-up beyond the 72-week milestone; Q4 topline remains a forecast. Estimated registry enrollment differs from the later sponsor count. Paris MASH announcements are not pivotal results. No systematic new biomarker-publication review.

### 2026-09-18 — Scheduled focused review

TGM-312 human development; NATiV3 and Paris MASH updates; discovery searches for new liver programs. The Duke resmetirom/HFpEF announcement was dated August 27, not September 16. Original event dates, safety and limitations are retained in the September 18 update above. The complete-topic successful-check date was not advanced because the listed gaps remain. [Run record](../updates/2026-09-18_scheduled_research_update.md).